Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of Phase III study ETV-022 in nucleoside-naive patients

被引：0
|
作者：
Chang, TT
Gish, R
de Man, R
Gadano, A
Sollano, J
Han, KH
Goodman, Z
Zhu, J
Cross, A
DeHertogh, D
Apelian, D
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[2] Calif Pacific Med Ctr, San Francisco, CA USA
[3] Erasmus Univ Hosp, Rotterdam, Netherlands
[4] H22 Hosp, Buenos Aires, DF, Argentina
[5] Univ Santo Tomas, Manila, Philippines
[6] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea
[7] Armed Forces Inst Pathol, Washington, DC 20306 USA
[8] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
ANTIVIRAL THERAPY | 2004年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：H21 / H22
页数：2
相关论文
共 50 条
  • [21] Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2-year results from a phase 3 study in nucleoside-naive patients in China (ETV-023)
    Yao, Guangbi
    Chen, ChengWei
    Lu, WeiLun
    Ren, Hong
    Tan, DeMing
    Wang, YuMing
    Xu, DaoZheng
    Liu, Jessica
    Xu, Dong
    MacDonald, Laurie
    HEPATOLOGY, 2006, 44 (04) : 559A - 560A
  • [22] Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients
    Sollano, J
    Schiff, E
    Carrilho, F
    Raptopoulou-Gigi, M
    Cooney, E
    Hindes, R
    Cross, A
    Dehertogh, D
    HEPATOLOGY, 2004, 40 (04) : 665A - 665A
  • [23] Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients
    Sollano, J
    Schiff, E
    Carrilho, F
    Raptopoulou-Gigi, M
    Cooney, E
    Hindes, R
    Cross, A
    DeHertogh, D
    ANTIVIRAL THERAPY, 2004, 9 (06) : H24 - H24
  • [24] Entecavir leads to sustained response off-treatment in nucleoside-naive, HBeAg(+) patients who met on-treatment response endpoints at 48 weeks of therapy in phase 3 study ETV-022
    Gish, RG
    Martin, P
    Schiff, ER
    De Man, RA
    Pederson, C
    Chang, TT
    Apelian, D
    Zhu, J
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A692 - A693
  • [25] Entecavir demonstrates consistent responses among baseline subgroups in the treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Brown, RS
    Lok, AS
    Gish, RG
    Schiff, ER
    Shouval, D
    Senturk, H
    Chang, TT
    Yurdaydin, C
    Apelian, D
    Fernandes, L
    Klesczewski, K
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A737 - A738
  • [26] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: Phase 2/3 safety results
    Gish, RG
    Sherman, M
    Lok, AS
    Pockros, PJ
    Raptopoulou-Gigi, M
    Sollano, JD
    Chang, TT
    Cooney, E
    Hindes, RG
    Yang, JY
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A693 - A693
  • [27] Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: Phase II/II safety results
    Manns, MP
    Raptopoulou-Gigi, M
    Sollano, J
    Gish, RG
    Chang, TT
    Sherman, M
    Yurdaydin, C
    Shouval, D
    Lok, AS
    Cooney, E
    Hindes, R
    Yang, J
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 185 - 185
  • [28] ETV re-treatment of nucleoside-naive HBeAG(-) patients
    Senturk, H.
    Lurie, Y.
    Gadano, A.
    Tan, C. K.
    Tran, T.
    Lee, S. D.
    Tsai, N.
    Cheinquer, H.
    Yang, J.
    Tamez, R.
    Hindes, R.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S197 - S197
  • [29] Histologic Improvement in Asian Patients With HBeAg(+) and HBeAg(-) Chronic Hepatitis B After Long-Term Treatment With Entecavir: Results From ETV-022,-027 and-901 Studies
    Tong, Myron J.
    Chang, Ting-Tsung
    Wu, Shun-Sheng
    Han, Kwang-Hyub
    Yoon, Seung Kew
    Pan, Calvin
    Kowdley, Kris
    Hu, Ke-Qin
    Goodman, Zachary
    Beebe, Suzanne
    Iloeje, Uchenna H.
    Tang, Hong
    GASTROENTEROLOGY, 2010, 138 (05) : S793 - S793
  • [30] The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Lurie, Y
    Manns, MP
    Gish, RG
    Chang, TT
    Yurdaydin, C
    Lai, CL
    Shouval, D
    Brown, RS
    Apelian, D
    Fernandes, L
    Klesczewski, K
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 184 - 184
12345